Dr. Raquibul Hannan

Claim this profile

ECOG-ACRIN Cancer Research Group

Studies Renal Cell Carcinoma
Studies Kidney Cancer
2 reported clinical trials
9 drugs studied

Affiliated Hospitals

Image of trial facility.

ECOG-ACRIN Cancer Research Group

Image of trial facility.

UT Southwestern Simmons Cancer Center - RedBird

Clinical Trials Raquibul Hannan is currently running

Image of trial facility.

Focused Radiation vs Systemic Therapy

for Kidney Cancer

This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where it first started (primary site) to a limited (2-5) number of places in the body (metastatic). Study doctors want to find out if this approach is better or worse than the usual approach for metastatic kidney cancer. The usual approach is defined as the care most people get for metastatic kidney cancer which includes systemic therapy such as immunotherapy (given through the veins) and/or small molecular inhibitor (tablets taken by mouth). Radiotherapy uses high energy x-rays to kill cancer cells and shrink tumors. SAbR uses special equipment to position a patient and deliver radiation to tumors with high precision. Giving SAbR prior to systemic therapy may kill more tumor cells than the usual approach, which is systemic therapy alone.

Recruiting

2 awards

Phase 3

19 criteria

Image of trial facility.

Stereotactic Radiation + Immunotherapy

for Kidney Cancer

This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.

Recruiting

1 award

Phase 2

21 criteria

More about Raquibul Hannan

Clinical Trial Related

2 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Raquibul Hannan has experience with

  • Stereotactic Ablative Radiotherapy
  • Systemic Therapy
  • Avelumab
  • Axitinib
  • Cabozantinib
  • Ipilimumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Raquibul Hannan specialize in?

Is Raquibul Hannan currently recruiting for clinical trials?

Are there any treatments that Raquibul Hannan has studied deeply?

What is the best way to schedule an appointment with Raquibul Hannan?

What is the office address of Raquibul Hannan?

Is there any support for travel costs?